MedTrace Logo

Ex Vivo LPS Stimulation in Healthy and Compromised Subjects

NCT01656915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2013-06-19

No results posted yet for this study

Summary

Ex vivo LPS stimulation of whole blood will be a good alternative challenge to induce an inflammatory response and examine differences in the inflammatory response between healthy and compromised subjects.

The purpose of the current study is to examine the inflammatory response in a younger population (35-45 yrs old) to see whether in this population also differences in the ex vivo LPS induced cytokine response exists between healthy and compromised subjects, as is seen in elderly subjects. Overweight subjects showing a state of disturbed blood glucose control will be included as subjects with compromised health and compared to healthy lean subjects with the same age (shifting from healthy towards unhealthy, not diseased).

Hypothesis Ex vivo LPS stimulation of whole blood will induce a measurable inflammatory cytokine response in a healthy population that is different from a response of the compromised population. The investigators will include subjects aged 35-45 years that differ in health characteristics, especially blood HbA1c, fat% and waist circumference.

Conditions

  • Compromised Health
  • Healthy

Sponsors & Collaborators

  • Unilever R&D

    collaborator INDUSTRY

  • Netherlands Metabolomic Center (NMC), The Netherlands

    collaborator UNKNOWN

  • TNO

    lead OTHER

Principal Investigators

  • Pierre Peeters, PhD · CHDR Leiden

Eligibility

Min Age
35 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-08-31
Completion
2012-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656915 on ClinicalTrials.gov